全文获取类型
收费全文 | 613篇 |
免费 | 54篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 17篇 |
基础医学 | 45篇 |
临床医学 | 34篇 |
内科学 | 391篇 |
皮肤病学 | 7篇 |
神经病学 | 5篇 |
特种医学 | 3篇 |
外科学 | 5篇 |
综合类 | 19篇 |
现状与发展 | 1篇 |
预防医学 | 2篇 |
药学 | 18篇 |
中国医学 | 2篇 |
肿瘤学 | 120篇 |
出版年
2024年 | 2篇 |
2023年 | 9篇 |
2022年 | 17篇 |
2021年 | 16篇 |
2020年 | 27篇 |
2019年 | 29篇 |
2018年 | 24篇 |
2017年 | 19篇 |
2016年 | 21篇 |
2015年 | 35篇 |
2014年 | 35篇 |
2013年 | 37篇 |
2012年 | 30篇 |
2011年 | 24篇 |
2010年 | 20篇 |
2009年 | 22篇 |
2008年 | 17篇 |
2007年 | 24篇 |
2006年 | 18篇 |
2005年 | 20篇 |
2004年 | 14篇 |
2003年 | 10篇 |
2002年 | 16篇 |
2001年 | 18篇 |
2000年 | 10篇 |
1999年 | 10篇 |
1998年 | 11篇 |
1997年 | 10篇 |
1996年 | 6篇 |
1995年 | 8篇 |
1994年 | 17篇 |
1993年 | 5篇 |
1992年 | 5篇 |
1991年 | 6篇 |
1990年 | 12篇 |
1989年 | 3篇 |
1988年 | 8篇 |
1987年 | 9篇 |
1986年 | 5篇 |
1985年 | 12篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 7篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 6篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
排序方式: 共有670条查询结果,搜索用时 15 毫秒
1.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
2.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
3.
4.
S B Wieslander B T Mortensen L Binderup N I Nissen 《European journal of haematology》1987,39(1):35-38
10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1 alpha(OH)D3, up to 4 micrograms daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 micrograms daily of 1 alpha(OH)D3 for a prolonged period up to 17 wk. The treatment with 1 alpha (OH)D3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH)2D3 were performed in 8 CLL patients and revealed only 1 patient with increased specific receptor binding capacity. The maximum tolerable dose of 1 alpha(OH)D3 varied individually, but was in the range of 2-4 micrograms daily. 相似文献
5.
脾切除治疗原发性骨髓纤维化适应证的探讨 总被引:1,自引:0,他引:1
目的:探讨脾切除治疗原发性骨髓纤维化的可行性及其效果。方法:回顾性分析我院2000年1月至2006年12月间收治的5例行脾切除治疗原发性骨髓纤维化的病人资料。结果:本组病人均行脾切除术,其中2例加行贲门周围血管离断术.术后发生脾窝积液1例,肺部感染1例。随访3月至5年,病人贫血状况、左上腹疼痛症状均得到缓解.生活质量得到改善。结论:脾切除对有适应证的原发性骨髓纤维化是可行的治疗手段,可明显改善病人的症状,提高生活质量。 相似文献
6.
7.
Juergen Thiele Hans Michael Kvasnicka Robert Fischer Volker Diehl 《Leukemia & lymphoma》1997,24(5):463-481
In this report an attempt has been made to discuss some of the issues pertinent to myelofibrosis complicating chronic myeloproliferative disorders (CMPDs) that are significantly associated with megakaryocyte function. In this context, biochemical, clinical and particularly morphological features were reviewed. Morphological findings based on elaborate techniques were in keeping with the assumption that in chronic myeloid leukemia (1) the number of CD61-positive megakaryocytes, and in particular their precursors were the parameters most closely associated with myelofibrosis (2) an increased content of reticulin fibers in follow-up biopsies significantly correlated with laboratory data indicative of a high tumor burden (anemia, peripheral blasts, hepatosplenomegaly) and thus a more advanced stage of the disease process (3) even a slight increase in reticulin, i.e. doubling of the normal fiber density was associated with a worse prognosis independent of therapeutic regimens given (4) Dynamics of myelofibrosis was significantly influenced by treatment. In this context, calculation of the myelofibrosis progression index (MPI) revealed a higher score following interferon therapy compared with busulfan. In addition, in idiopathic myelofibrosis (5) the evolution of myelofibrosis was unpredictable and according to the MPI, progression occurred at a relatively low rate (6) proliferation and dilatation of sinusoids accompanying intravascular hematopoiesis and collagen type IV deposits were predominant features in later (fibro-osteosclerotic) stages in the course of disease (7) transmural migration of megakaryocytes demonstrated by three dimensional reconstruction revealed a mole-like tunneling through the thickened sinusoidal wall. A very careful assessment of the numerous correlations between bone marrow features and laboratory data will allow clinicians and pathologists to gain a better insight into the mutual relationships between hematological and morphological findings in CMPDs. 相似文献
8.
Bella Shadur Nathalie Asherie Peter E. Newburger Polina Stepensky 《Pediatric blood & cancer》2019,66(1)
Mutations in the VPS45 gene lead to a severe primary immune deficiency characterized by severe congenital neutropenia and primary myelofibrosis, leading to overwhelming infection and early death. This condition is exceedingly rare with only 16 patients previously reported, including four with successful hematopoietic stem cell transplantation. We review the pathophysiology underlying this condition and detail our approach to treatment, particularly vis‐à‐vis bone marrow transplantation and the challenges of transplanting into a diseased bone marrow niche. We provide an update on the progress of our three previously reported patients, and two additional patients transplanted at our center. 相似文献
9.
目的研究原发性骨髓纤维化早期和纤维化期骨髓形态学差异。方法分析42例标本中纤维化早期与纤雏化期骨髓形态学差异。结果纤维化早期与纤堆化期除年龄外,共余临床指标均存在显著差异(P〈0.05)。结论骨髓形态学对PMF早期与纤维化期鉴别具有重要价值。 相似文献
10.
Predictive factors for anemia response to erythropoiesis‐stimulating agents in myelofibrosis 下载免费PDF全文
Juan‐Carlos Hernández‐Boluda Juan‐Gonzalo Correa Regina García‐Delgado Joaquín Martínez‐López Alberto Alvarez‐Larrán María‐Laura Fox Valentín García‐Gutiérrez Manuel Pérez‐Encinas Francisca Ferrer‐Marín María‐Isabel Mata‐Vázquez José‐María Raya Natalia Estrada Silvia García Ana Kerguelen María‐Antonia Durán Manuel Albors Francisco Cervantes 《European journal of haematology》2017,98(4):407-414